Genzyme (GENZ) Stock Research, Analysis & News

Quick Analysis on Genzyme (GENZ) Stock as of November 22, 2018

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Genzyme (GENZ) Stock below)

Genzyme (GENZ) Stock Profile Summary

Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. The companys Genetic Diseases segment manufactures and distributes Cerezyme for the treatment of Gaucher disease; Fabrazyme for the treatment of Fabry disease; Myozyme for the treatment of Pompe disease; Aldurazyme for the treatment of Mucopolysaccharidosis I; and Elaprase for the treatment of Mucopolysaccharidosis II. Its Cardiometabolic and Renal segment offers Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. The companys Biosurgery segment provides Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, including Campath and Fludara for the treatment of leukemia and lymphoma; Clolar for the treatment of acute leukemia; Leukine for the reduction of the incidence of severe and life-threatening infections in older adult patients with AML following chemotherapy and certain other uses; and Mozobil for the mobilization of hematopoietic stem cells. The company has strategic alliances with Bayer; Osiris Therapeutics, Inc.; PTC Therapeutics, Inc.; and Isis Pharmaceuticals, Inc. It serves physicians, hospitals, treatment centers, other providers of medication to patients, retail pharmacies, and government agencies through distributors. The company was founded in 1981 and is based in Cambridge, Massachusetts.

Genzyme (GENZ) Stock Key Statistics Research and Analysis as of November 22, 2018

Genzyme (GENZ) Stock Competitor Research and Analysis

Amicus Therapeutics, Inc. (FOLD)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Latest Market News on Genzyme (GENZ)


Click here to find the latest news on Genzyme (GENZ)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Amicus Therapeutics, Inc. (FOLD)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)